{"id":121039,"date":"2021-04-13T19:55:24","date_gmt":"2021-04-13T19:55:24","guid":{"rendered":"https:\/\/precoinnews.com\/?p=121039"},"modified":"2021-04-13T19:55:24","modified_gmt":"2021-04-13T19:55:24","slug":"u-s-pauses-use-of-jj-vaccine-over-rare-blood-clots-rollout-delayed-in-europe","status":"publish","type":"post","link":"https:\/\/precoinnews.com\/markets\/u-s-pauses-use-of-jj-vaccine-over-rare-blood-clots-rollout-delayed-in-europe\/","title":{"rendered":"U.S. pauses use of J&J vaccine over rare blood clots, rollout delayed in Europe"},"content":{"rendered":"
(Reuters) – U.S. federal health agencies on Tuesday recommended pausing use of Johnson & Johnson\u2019s COVID-19 vaccine for at least a few days after six women under age 50 developed rare blood clots after receiving the shot, dealing a fresh setback to efforts to tackle the pandemic.<\/p>\n
Johnson & Johnson said it would delay rollout of the vaccine to Europe, a week after regulators there said they were reviewing rare blood clots in four recipients of the shot in the United States. South Africa also suspended use of J&J\u2019s vaccine.<\/p>\n
Acting U.S. Food and Drug Administration Commissioner Janet Woodcock said the agency expected the pause to be a matter of days, and was aimed at providing information to healthcare providers on how to diagnose and treat the clots.<\/p>\n
The moves come after European regulators said earlier this month they had found a possible link between AstraZeneca\u2019s COVID-19 vaccine and a similar rare blood clotting problem that led to a small number of deaths.<\/p>\n
FDA official Peter Marks said it was \u201cplainly obvious\u201d the J&J cases were \u201cvery similar\u201d to the AstraZeneca ones. He said there had been no similar blood clot cases reported among recipients of the Moderna or Pfizer\/BioNTech vaccines, which use a different technology and accounted for the vast majority of U.S. vaccinations so far.<\/p>\n
But J&J\u2019s single-dose shot and AstraZeneca\u2019s low-cost vaccine are seen as vital weapons in the fight against a pandemic that has claimed more than three million lives.<\/p>\n
Immunology experts echoed U.S. officials in underscoring that the risk posed by the J&J vaccine appeared extremely low.<\/p>\n
Related Coverage<\/p>\n<\/p>\n
See more stories